跳至主要内容
临床试验/NL-OMON50651
NL-OMON50651招募中不适用

Infusion VErsus STimulation, a cost-effectiveness analysis of the treatment in advanced Parkinson's disease comparing Continuous Intrajejunal Levodopa Infusion to the traditional standard treetment Deep Brain Stimulation; - INVEST (Infusion VErsus STimulation) study

Academisch Medisch Centrum0 个研究点目标入组 66 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
66

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - idiopathic Parkinson's Disease with bradykinesia and at least two of the
  • following signs; resting tremor, rigidity, and asymmetry;
  • - despite optimal pharmacological treatment, at least one of the following
  • symptoms: severe response fluctuations, dyskinesias, painful dystonia or
  • bradykinesia;
  • -a life expectancy of at least two years.

排除标准

  • -age below 18 years
  • - previous PD-neurosurgery (e.g., DBS, pallidotomy, thalamotomy);
  • - previous CLI (through a PEG-tube or Nasal Jejuna| tube);
  • - Hoehn and Yahr stage 5 at the best moment during the day;
  • - dementia or indication for severe cognitive impairment, such as PD-CRS <65;
  • - psychosis;
  • - current depression;
  • - other, severely disabling condition;
  • - contraindications for DBS surgery, such as a physical disorder making surgery
  • - contraindications for PEG surgery such as interposed organs, ascites and
  • oesophagogastric varices, or for Duodopa;
  • - pregnancy, breastfeeding, and women of child bearing age not using a reliable
  • method of contraception;
  • - No informed consent;
  • - legally incompetent adults.

研究者

相似试验